Rationale
The 11th “Milan Congress on Innovative Anticancer Therapy” will present leading international
experts in the field of immuno-oncology and cancer cell signaling to investigate the potentials,
opportunities and challenges of immunotherapy and targeted therapies. The newest therapeutic
approaches will be discussed in the context of the COVID-19 epidemic.
Increased knowledge of the molecular mechanisms responsible for neoplastic transformation, the
biology of cancer cells, and the immunological mechanisms regulating tumor-host interaction, has
allowed us to identify and apply more effective biological and immunological anticancer treatments.
To date, immuno-biotherapy is a continuously evolving treatment modality and is currently
integrated into the treatment algorithms of several different tumor types. Combination treatments
based on immune checkpoint inhibitors (ICI) with either targeted therapy, radiotherapy or
standard chemotherapy have recently been introduced in clinical practice. Rationale, pro and contra,
and the identification of a specific subset of patients who could benefit from these approaches will
be discussed.
This conference explores topics that will appeal to clinicians, as well as to, basic, translational, and
clinical scientists ranging from academia to industry. As in the past, the meeting will provide a
highly interactive forum in which leading experts will discuss clinical and pre-clinical data, and provide
the audience with a broad overview of the most recent achievements in biological and immunological
cancer therapy.
Lastly, a wide spectrum of evolving topics in cancer research such as epigenetic drugs and CART cells
will be analyzed in view of their introduction in the clinical setting.
